MRSN Insider Trading Activity and SEC Form 4 Filings
MRSN insider trading summary
No open-market insider purchases or sales of Mersana Therapeutics, Inc. (MRSN) have been reported on SEC Form 4 in the past 12 months.
Latest MRSN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 27, 2025 | Mohan Bala | SVP, Chief Development Officer | Sell | $762 (77 @ $9.90) |
| Sep 12, 2025 | Martin H. Huber Jr. | President, CEO | Sell | $15K (2,012 @ $7.31) |
| Jan 16, 2025 | Brian DeSchuytner | SVP, COO & CFO | Sell | $5K (8,470 @ $0.58) |
| Jan 16, 2025 | Timothy B Lowinger | SVP, Chief Sci.&Tech. Officer | Sell | $5K (8,048 @ $0.58) |
| Jan 16, 2025 | Alejandra Carvajal | SVP, Chief Legal Officer | Sell | $3K (5,096 @ $0.58) |
| Jan 16, 2025 | Martin H. Huber Jr. | President, CEO | Sell | $3K (4,514 @ $0.58) |
| Jan 16, 2025 | Ashish Mandelia | VP, Chief Accounting Officer | Sell | $2K (3,554 @ $0.58) |
| Jan 16, 2025 | Mohan Bala | SVP, Chief Development Officer | Sell | $3K (5,939 @ $0.58) |
| Jan 16, 2025 | Anna Protopapas | Director | Sell | $5K (8,637 @ $0.58) |
| Jan 15, 2025 | Anna Protopapas | Director | Sell | $4K (6,191 @ $0.63) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.